newsfilter
← Earnings
Earnings Releases·

Avalo Therapeutics — Third Quarter 2026 Earnings Summary

Avalo Therapeutics reported a net loss of $18.9 million for the third quarter of 2026, with cash, cash equivalents, and investments totaling $462.8 million as of September 30, 2026. The company plans to initiate a registrational Phase 3 program for its lead candidate abdakibart in hidradenitis suppurativa during the first half of 2027. Additionally, an Investigational New Drug submission for the next-generation antibody AVTX-010 is anticipated in the same timeframe. These developments are supported by a financial runway expected to fund operations into 2029.

Company
AVALO THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology